Next Article in Journal
Bacterial Cellulose as a Potential Bio-Scaffold for Effective Re-Epithelialization Therapy
Next Article in Special Issue
Customisable Tablet Printing: The Development of Multimaterial Hot Melt Inkjet 3D Printing to Produce Complex and Personalised Dosage Forms
Previous Article in Journal
Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery
Previous Article in Special Issue
Selection and Incorporation of siRNA Carrying Non-Viral Vector for Sustained Delivery from Gellan Gum Hydrogels
Review

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Marta González-Álvarez
Pharmaceutics 2021, 13(10), 1591; https://doi.org/10.3390/pharmaceutics13101591
Received: 8 August 2021 / Revised: 22 September 2021 / Accepted: 27 September 2021 / Published: 30 September 2021
(This article belongs to the Special Issue Controlled Delivery Formulations (Volume II))
There have been many efforts to improve oral drug bioavailability and therapeutic efficacy and patient compliance. A variety of controlled-release oral delivery systems have been developed to meet these needs. Gastroretentive drug delivery technologies have the potential to achieve retention of the dosage form in the upper gastrointestinal tract (GIT) that can be sufficient to ensure complete solubilisation of the drugs in the stomach fluids, followed by subsequent absorption in the stomach or proximal small intestine. This can be beneficial for drugs that have an “absorption window” or are absorbed to a different extent in various segments of the GIT. Therefore, gastroretentive technologies in tandem with controlled-release strategies could enhance both the therapeutic efficacy of many drugs and improve patient compliance through a reduction in dosing frequency. The paper reviews different gastroretentive drug delivery technologies and controlled-release strategies that can be combined and summarises examples of formulations currently in clinical development and commercially available gastroretentive controlled-release products. The different parameters that need to be considered and monitored during formulation development for these pharmaceutical applications are highlighted. View Full-Text
Keywords: stomach; absorption window; gastric retention; gastroretentive drug delivery systems; controlled release; patient compliance stomach; absorption window; gastric retention; gastroretentive drug delivery systems; controlled release; patient compliance
Show Figures

Figure 1

MDPI and ACS Style

Vrettos, N.-N.; Roberts, C.J.; Zhu, Z. Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications. Pharmaceutics 2021, 13, 1591. https://doi.org/10.3390/pharmaceutics13101591

AMA Style

Vrettos N-N, Roberts CJ, Zhu Z. Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications. Pharmaceutics. 2021; 13(10):1591. https://doi.org/10.3390/pharmaceutics13101591

Chicago/Turabian Style

Vrettos, Napoleon-Nikolaos, Clive J. Roberts, and Zheying Zhu. 2021. "Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications" Pharmaceutics 13, no. 10: 1591. https://doi.org/10.3390/pharmaceutics13101591

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop